Reference health
Phase <scp>I</scp> clinical trial of adoptive transfer of expanded natural killer cells in combination with <scp>I</scp>g<scp>G</scp>1 antibody in patients with gastric or colorectal cancer
37/37 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 37 checked references that resolve
resolves10.1126/science.1068440
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
resolves10.1182/blood-2011-06-360255
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
resolves10.1182/blood-2005-08-027979
Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
resolves10.1111/j.1537-2995.2006.01145.x
Good manufacturing practices production of natural killer cells for immunotherapy: a six‐year single‐institution experience
resolves10.1371/journal.pone.0009221
High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
resolves10.1158/0008-5472.CAN-08-3712
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
resolves10.1007/s00262-014-1614-z
Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients
resolves10.3389/fonc.2013.00118
Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol
resolves10.1186/s12967-015-0632-8
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer
resolves10.1158/1078-0432.CCR-04-0225
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
resolves10.1158/0008-5472.CAN-07-2068
Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2
resolves10.1186/1471-2407-10-340
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
resolves10.1056/NEJMoa070594
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
resolves10.1056/NEJM199501193320303
Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy
resolves10.1371/journal.pone.0083786
Phase I Clinical Trial of Fibronectin CH296-Stimulated T Cell Therapy in Patients with Advanced Cancer
resolves10.1016/j.clinbiochem.2011.09.007
Relationship between circulating cytokine levels and physical or psychological functioning in patients with advanced cancer
resolves10.1002/ijc.28117
Whole blood interferon‐γ levels predict the therapeutic effects of adoptive T‐cell therapy in patients with advanced pancreatic cancer
resolves10.1089/jir.1996.16.911
Determination of Interferon-α-Producing Capacity in Whole Blood Cultures from Patients with Various Diseases and from Healthy Persons
resolves10.1093/annonc/mdu472
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
resolves10.1038/bjc.2014.18
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
resolves10.1200/JCO.2008.20.8397
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
resolves10.1245/s10434-015-4771-1
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)
resolves10.1158/1535-7163.MCT-15-0879
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
resolves10.1371/journal.pone.0157830
Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
resolves10.1126/scitranslmed.3002842
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
resolves10.1056/NEJMoa1103849
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
resolves10.3892/etm.2011.271
Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells
resolves10.1158/1078-0432.CCR-07-0865
The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines
resolves10.1002/eji.1830241206
Stimulated natural killer cells secrete factors with chemotactic activity, including NAP‐1/IL‐8, which supports VLA‐4‐ and VLA‐5‐mediated migration of T lymphocytes
resolves10.1111/j.1600-065X.2006.00445.x
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
resolves10.1084/jem.20122248
Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2
resolves10.1158/2326-6066.CIR-15-0118
Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
The 2 references without a DOI — listed, not checked
no DOI — not checkedIdenoM KatoA EnokiT et al. A robust and selective expansion method for functional NK cells and its application forin vivoADCC evaluation system The 5th meeting of Asian Cellular Therapy Organization Osaka Japan 2014.
no DOI — not checkedDifferential interleukin 12 responsiveness for interferon gamma production in advanced stages of cancer patients correlates with performance status
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1002/ijc.31285"><img src="https://citestamp.com/citestamped/10.1002/ijc.31285/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1002/ijc.31285)